Plasma 25-Hydroxyvitamin D3 and bladder cancer risk according to tumor stage and FGFR3 status: A mechanism-based epidemiological study

Journal of the National Cancer Institute

Volumn 104, Issue 24, 2012, Pages 1897-1904

  Amaral, André F S ^a   Méndez Pertuz, Marinela ^b   Muñoz, Alberto ^a,c   Silverman, Debra T ^d   Allory, Yves ^e   Kogevinas, Manolis ^f,g   Lloreta, Josep ^f,h   Rothman, Nathaniel ^d   Carrato, Alfredo ^i,j   Rivas Del Fresno, Manuel ^k   Real, Francisco X ^b,h   Malats, Núria ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b Epithelial Carcinogenesis Group   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^d NATIONAL CANCER INSTITUTE   (United States)

^e INSERM U955   (France)

^f HOSPITAL DEL MAR   (Spain)

^g NATIONAL SCHOOL OF PUBLIC HEALTH   (Greece)

^h UNIVERSITAT POMPEU FABRA   (Spain)

ⁱ HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^j HOSPITAL RAMÓN Y CAJAL   (Spain)

^k HOSPITAL DE CABUEÑES   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CALCIFEDIOL; CALCITRIOL; FIBROBLAST GROWTH FACTOR RECEPTOR 3; MESSENGER RNA;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER INVASION; CANCER RISK; CANCER STAGING; CELL PROLIFERATION; CHEMILUMINESCENCE IMMUNOASSAY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOKING; UPREGULATION;

ADULT; AGED; ANTICARCINOGENIC AGENTS; BLOTTING, WESTERN; CALCIFEDIOL; CASE-CONTROL STUDIES; CELL PROLIFERATION; EUROPE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOASSAY; LOGISTIC MODELS; LUMINESCENT MEASUREMENTS; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; ODDS RATIO; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RISK ASSESSMENT; RISK FACTORS; RNA, MESSENGER; SPAIN; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; URINARY BLADDER NEOPLASMS;

EID: 84871831687     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs444     Document Type: Article

References (40)

1. Garland CF, Gorham ED, Mohr SB, et al. Vitamin D for cancer prevention: global perspective. Ann Epidemiol. 2009;19(7):468-483.
2. Giovannucci E. The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). Cancer Causes Control. 2005;16(2):83-95.
3. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266-281.
4. Fedirko V, Bostick RM, Long Q, et al. Effects of supplemental vitamin D and calcium on oxidative DNA damage marker in normal colorectal mucosa: a randomized clinical trial. Cancer Epidemiol Biomarkers Prev. 2010;19(1):280-291.
5. Touvier M, Chan DSM, Lau R, et al. Meta-analyses of vitamin D intake, 25-hydroxyvitamin D status, vitamin D receptor polymorphisms and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2011;20(5):1003-1016.
6. Yin L, Grandi N, Raum E, et al. Meta-analysis: serum vitamin D and breast cancer risk. Eur J Cancer. 2010;46(12):2196-2205.
7. Helzlsouer KJ. Overview of the cohort consortium vitamin D pooling project of rarer cancers. Am J Epidemiol. 2010;172(1):4-9.
8. Albanes D, Mondul AM, Yu K, et al. Serum 25-hydroxy vitamin D and prostate cancer risk in a large nested case-control study. Cancer Epidemiol Biomarkers Prev. 2011;20(9):1850-1860.
9. Yin L, Raum E, Haug U, et al. Meta-analysis of longitudinal studies: serum vitamin D and prostate cancer risk. Cancer Epidemiol. 2009;33(6):435-445.
10. Wolpin BM, Ng K, Bao Y, et al. Plasma 25-hydroxyvitamin D and risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2012;21(1):82-91.
11. Shui IM, Mucci LA, Kraft P, et al. Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study. J Natl Cancer Inst. 2012;104(9):690-699.
12. Silverman D, Devesa S, Moore L, et al. Bladder cancer. In: Schottenfeld D, Fraumeni J Jr, eds. Cancer Epidemiology and Prevention. 3rd ed. New York: Oxford University Press; 2006:1101-1127.
13. Samanic C, Kogevinas M, Dosemeci M, et al. Smoking and bladder cancer in Spain: effects of tobacco type, timing, environmental tobacco smoke, and gender. Cancer Epidemiol Biomarkers Prev. 2006;15(7):1348-1354.
14. Mondul AM, Weinstein SJ, Mannisto S, et al. Serum vitamin D and risk of bladder cancer. Cancer Res. 2010;70(22):9218-9223.
15. Mondul AM, Weinstein SJ, Horst RL, et al. Serum vitamin D and risk of bladder cancer in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev. 2012;21(7):1222-1225.
16. Konety BR, Lavelle JP, Pirtskalaishvili G, et al. Effects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo. J Urol. 2001;165(1):253-258.
17. Sahin MO, Canda AE, Yorukoglu K, et al. 1,25 Dihydroxyvitamin D(3) receptor expression in superficial transitional cell carcinoma of the bladder: a possible prognostic factor? Eur Urol. 2005;47(1):52-57.
18. Luis NM, Lopez-Knowles E, Real FX. Molecular biology of bladder cancer. Clin Transl Oncol. 2007;9(1):5-12.
19. Hernandez S, Lopez-Knowles E, Lloreta J, et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol. 2006;24(22):3664-3671.
20. Garcia-Closas M, Malats N, Silverman D, et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet. 2005;366(9486):649-659.
21. Epstein JI, Amin MB, Reuter VR, et al. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol. 1998;22(12):1435-1448.
22. Mostofi F, Davis C, Sesterhenn I. Histological typing of urinary bladder tumours. Berlin: Springer; 1999.
23. van Dam RM, Snijder MB, Dekker JM, et al. Potentially modifiable determinants of vitamin D status in an older population in the Netherlands: the Hoorn Study. Am J Clin Nutr 2007;85(3):755-761.
24. Jaaskelainen T, Knekt P, Marniemi J, et al. Vitamin D status is associated with sociodemographic factors, lifestyle and metabolic health [published online ahead of print April 27, 2012]. Eur J Nutr. 2012. doi:10.1007/s00394-012-0354-0.
25. Kinyamu HK, Gallagher JC, Rafferty KA, et al. Dietary calcium and vitamin D intake in elderly women: effect on serum parathyroid hormone and vitamin D metabolites. Am J Clin Nutr. 1998;67(2):342-348.
26. Looker AC, Pfeiffer CM, Lacher DA, et al. Serum 25-hydroxyvitamin D status of the US population: 1988-1994 compared with 2000-2004. Am J Clin Nutr. 2008;88(6):1519-1527.
27. Jebar AH, Hurst CD, Tomlinson DC, et al. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene. 2005;24(33):5218-5225.
28. Tomlinson DC, Baldo O, Harnden P, et al. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol. 2007;213(1):91-98.
29. Palmer HG, Larriba MJ, Garcia JM, et al. The transcription factor SNAIL represses vitamin D receptor expression and responsiveness in human colon cancer. Nat Med. 2004;10(9):917-919.
30. Palmer HG, Gonzalez-Sancho JM, Espada J, et al. Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J Cell Biol. 2001;154(2):369-387.
31. Pereira F, Barbachano A, Silva J, et al. KDM6B/JMJD3 histone demethylase is induced by vitamin D and modulates its effects in colon cancer cells. Hum Mol Genet. 2011;20(23):4655-4665.
32. Gonzalez-Padilla E, Soria Lopez A, Gonzalez-Rodriguez E, et al. High prevalence of hypovitaminosis D in medical students in Gran Canaria. Canary Islands (Spain). Endocrinol Nutr. 2011;58(6):267-273.
33. Gonzalez-Molero I, Morcillo S, Valdes S, et al. Vitamin D deficiency in Spain: a population-based cohort study. Eur J Clin Nutr. 2011;65(3):321-328.
34. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev. 2001;22(4):477-501.
35. Melhus H, Snellman G, Gedeborg R, et al. Plasma 25-hydroxyvitamin D levels and fracture risk in a community-based cohort of elderly men in Sweden. J Clin Endocrinol Metab. 2010;95(6):2637-2645.
36. Looker AC, Johnson CL, Lacher DA, et al. Vitamin D status: United States, 2001-2006. NCHS Data Brief. 2011;59:1-8.
37. Hofmann JN, Yu K, Horst RL, et al. Long-term variation in serum 25-hydroxyvitamin D concentration among participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev. 2010;19(4):927-931.
38. Zeleniuch-Jacquotte A, Gallicchio L, Hartmuller V, et al. Circulating 25-hydroxyvitamin D and risk of endometrial cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol. 2010;172(1):36-46.
39. Meng JE, Hovey KM, Wactawski-Wende J, et al. Intraindividual variation in plasma 25-hydroxyvitamin D measures 5 years apart among postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2012;21(6):916-924.
40. Saliba W, Barnett O, Stein N, et al. The longitudinal variability of serum 25(OH)D levels. Eur J Intern Med. 2012;23(4):e106-e111.